Podrid P J
J Clin Pharmacol. 1984 Jul;24(7):313-9. doi: 10.1002/j.1552-4604.1984.tb01840.x.
The recognition that certain types of ventricular premature beats, specifically repetitive forms, may be forerunners of more serious tachyarrhythmias has led to the practice of prophylactic therapy with antiarrhythmic drugs to suppress these forms in patients who have underlying cardiac disease. Several antiarrhythmic drugs are available for oral therapy, and many others are undergoing investigation. The usefulness of these agents is often limited by frequent side effects, which include idiosyncratic and unpredictable reactions that are not related to drug level. One such effect is the aggravation of the arrhythmia being treated. Noninvasive drug testing in 245 patients for a total of 1024 single drug tests showed 113 studies (11 per cent) to have been aggravated by the antiarrhythmic drug. At least one drug was proarrhythmic in 78 patients (32 per cent). Aggravation of arrhythmia is a potentially serious drug complication that occurs with all antiarrhythmic agents.
认识到某些类型的室性早搏，特别是重复性形式，可能是更严重的快速心律失常的先兆，这导致了在患有潜在心脏病的患者中使用抗心律失常药物进行预防性治疗以抑制这些形式的做法。有几种抗心律失常药物可用于口服治疗，还有许多其他药物正在进行研究。这些药物的有效性常常受到频繁副作用的限制，这些副作用包括与药物水平无关的特异质性和不可预测的反应。其中一种效应是正在治疗的心律失常加重。对245例患者进行的24小时无创药物测试，总共进行了1024次单药测试，结果显示有113项研究（11%）的心律失常因抗心律失常药物而加重。至少有一种药物在78例患者（32%）中具有促心律失常作用。心律失常加重是一种潜在的严重药物并发症，所有抗心律失常药物都会出现这种情况。
